Search results for Merck Sharp & Dohme LLC - Clinical Trials Registry - ICH GCP

Example: Heart Attack

Clinical Trials Sponsored by Merck Sharp & Dohme LLC

Total 1255 results

NCT05665595

Recruiting

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

Conditions: Melanoma
NCT05656040

Recruiting

A Study of MK-2060 in Participants With Chronic Kidney Disease (MK-2060-011)

Conditions: End-Stage Renal Disease, End-Stage Kidney Disease, Kidney Failure, Chronic
NCT05027074

Recruiting

Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)

Conditions: End-Stage Renal Disease, End-Stage Kidney Disease, Kidney Failure, Chronic
NCT04663321

Recruiting

Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)

Conditions: Treatment Resistant Depression
NCT04014530

Recruiting

Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study

Conditions: Colorectal Cancer, Endometrium Cancer
NCT03611868

Recruiting

A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Conditions: Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation, MDM2 Gene Mutation, MPNST, Cutaneous Melanoma, Mucosal Melanoma, Malignant Peripheral Nerve Sheath Tumors
NCT05708950

Not yet recruiting

A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors

Conditions: Cancer, Solid Tumor, Melanoma, Carcinoma, Sarcoma, Lung Cancer, Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Uterine Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Thyroid Cancer, Ovarian Cancer, Kidney Cancer, Head and Neck Cancer
NCT05406440

Active, not recruiting

A Study of MK-8189 in Participants With Schizophrenia (MK-8189-014)

Conditions: Schizophrenia
NCT04730635

Active, not recruiting

Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)

Conditions: Alzheimer's Disease, Mild Cognitive Impairment
NCT02184195

Active, not recruiting

Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

Conditions: Germline BRCA1/2 Mutations and, Metastatic Adenocarcinoma of the Pancreas
NCT04892472

Recruiting

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Advanced Non-small Cell Lung Cancer (NSCLC)

Conditions: Non-small Cell Lung Cancer
NCT04353973

Recruiting

Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Cancer Patients

Conditions: Cancer
NCT05706779

Not yet recruiting

Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer

Conditions: Colorectal Cancer, BRAF V600E Mutation Positive
NCT01953458

Active, not recruiting

Therapeutic Option for Hepatitis B and C: a French Cohort

Conditions: Viral Hepatitis B, Viral Hepatitis C
NCT03316573

Suspended

Pembrolizumab in Neoplasms or Lymphomas

Conditions: Lymphoma, Histiocytic Sarcoma, Follicular Dendritic Cell Sarcoma, Interdigitating Dendritic Cell Sarcoma
NCT05609968

Recruiting

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

Conditions: Carcinoma, Non-Small-Cell Lung
NCT05298423

Recruiting

Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006)

Conditions: Carcinoma, Non-Small-Cell Lung
NCT05239728

Recruiting

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

Conditions: Clear Cell Renal Cell Carcinoma
NCT05226598

Recruiting

Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)

Conditions: Metastatic Non-Small Cell Lung Cancer
NCT05224141

Recruiting

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008, KEYVIBE-008)

Conditions: Small Cell Lung Carcinoma
NCT05007106

Recruiting

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

Conditions: Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck, Gallbladder Neoplasms, Cholangiocarcinoma, Esophageal Neoplasms, Triple Negative Breast Neoplasms, Hepatocellular Carcinoma, Urinary Bladder Neoplasms, Ovarian Neoplasms, Stomach Neoplasms
NCT05005442

Recruiting

A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)

Conditions: Hematological Malignancies
NCT04924075

Recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), or Von Hippel-Lindau (VHL) Disease-Associated Tumors (MK-6482-015)

Conditions: Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease
NCT04846920

Recruiting

A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)

Conditions: Carcinoma, Renal Cell
NCT04738487

Recruiting

Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)

Conditions: Lung Neoplasms, Non-Small-Cell Lung Carcinoma